الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Ophthalmology>>17-trifluoromethylphenyl trinor Prostaglandin F2α

17-trifluoromethylphenyl trinor Prostaglandin F2α (Synonyms: 17trifluoromethylphenyl trinor PGF2α)

رقم الكتالوجGC41975

A number of 17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma.

Products are for research use only. Not for human use. We do not sell to patients.

17-trifluoromethylphenyl trinor Prostaglandin F2α التركيب الكيميائي

Cas No.: 221246-34-0

الحجم السعر المخزون الكميّة
1mg
83٫00
متوفر
5mg
378٫00
متوفر
10mg
672٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

A number of 17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma. Of these, the unsubstituted or meta-substituted aromatic derivatives are the most potent FP receptor agonists. 17-trifluoromethylphenyl trinor PGF2α bears an aromatic ring which is reminiscent of the trifluoromethyl-phenoxy ring of travoprost ((+)-fluprostenol isopropyl ester). As an ocular hypotensive agent, it would be expected that 17-trifluoromethylphenyl trinor PGF2α would act very much like the free acid of travoprost. 17-phenyl trinor PGF2α is a potent luteolytic and abortifacient, with a potency equal to or greater than fluprostenol and cloprostenol.

مراجعات

Review for 17-trifluoromethylphenyl trinor Prostaglandin F2α

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 17-trifluoromethylphenyl trinor Prostaglandin F2α

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.